The in vitro experiments conducted by Chen Y and colleagues also showed that the combination of TNF-α antibody adalimumab and anti-IL-1β antibody simultaneously can exert a synergistic effect in preventing endothelial cell activation, suggesting that blocking TNF-α and IL-1β may have therapeutic potential for CAR-T related CRS and ICANS [40]. This evidence concerns the gene TNF and congenital rubella syndrome.